

Jeremy Tomlinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3913950/publications.pdf>

Version: 2024-02-01

178
papers

14,227
citations

26567

56
h-index

21474

114
g-index

184
all docs

184
docs citations

184
times ranked

13896
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e538-e547.	2.4	12
2	Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. <i>Clinical Endocrinology</i> , 2022, 96, 200-219.	1.2	46
3	Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. <i>European Journal of Endocrinology</i> , 2022, 186, 367-377.	1.9	12
4	Sex hormones, adiposity, and metabolic traits in men and women: a Mendelian randomisation study. <i>European Journal of Endocrinology</i> , 2022, 186, 407-416.	1.9	17
5	Is it time for chronopharmacology in NASH?. <i>Journal of Hepatology</i> , 2022, 76, 1215-1224.	1.8	20
6	AKR1D1 knockout mice develop a sex-dependent metabolic phenotype. <i>Journal of Endocrinology</i> , 2022, 253, 97-113.	1.2	7
7	Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents. <i>Metabolism Open</i> , 2022, 14, 100177.	1.4	6
8	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 755-769.	3.7	34
9	Is autonomous cortisol secretion sexually dimorphic?. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 473-475.	5.5	1
10	Increased systemic and adipose 11 β -HSD1 activity in idiopathic intracranial hypertension. <i>European Journal of Endocrinology</i> , 2022, 187, 323-333.	1.9	11
11	Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment. <i>Liver International</i> , 2022, 42, 1772-1782.	1.9	7
12	11 β -HSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 174-187.	1.8	39
13	Differential activity and expression of human 5 α -reductase (AKR1D1) splice variants. <i>Journal of Molecular Endocrinology</i> , 2021, 66, 181-194.	1.1	3
14	The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 207, 105808.	1.2	9
15	International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry. <i>European Journal of Endocrinology</i> , 2021, 184, 553-563.	1.9	21
16	Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. <i>JCI Insight</i> , 2021, 6, .	2.3	45
17	Extensive weight loss reduces glycan age by altering IgG N-glycosylation. <i>International Journal of Obesity</i> , 2021, 45, 1521-1531.	1.6	29
18	Gonadectomy in conditions affecting sex development: a registry-based cohort study. <i>European Journal of Endocrinology</i> , 2021, 184, 791-801.	1.9	9

#	ARTICLE	IF	CITATIONS
19	Sleep and liver disease: a bidirectional relationship. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 850-863.	3.7	36
20	Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance. <i>Diabetes</i> , 2021, 70, 364-376.	0.3	23
21	SP5.1.5 Bariatric surgery is associated with greater survival and metabolic health benefits than conventional medical management in people with NAFLD. <i>British Journal of Surgery</i> , 2021, 108, .	0.1	0
22	Glucocorticoids in pregnancy. <i>Obstetric Medicine</i> , 2020, 13, 62-69.	0.5	17
23	Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 314-326.	1.8	30
24	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <i>Endocrine Reviews</i> , 2020, 41, 66-117.	8.9	134
25	Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. <i>JGH Open</i> , 2020, 4, 433-440.	0.7	10
26	Perioperative corticosteroid supplementation for patients on therapeutic glucocorticoids: a national survey. <i>Anaesthesia</i> , 2020, 75, 1396-1398.	1.8	2
27	The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G345-G360.	1.6	20
28	Altered cortisol metabolism in individuals with HNF1A-MODY. <i>Clinical Endocrinology</i> , 2020, 93, 269-279.	1.2	4
29	Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1205-1206.	1.9	0
30	Co-administration of 5 α -reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3316-e3328.	1.8	9
31	The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 202, 105724.	1.2	13
32	11 β -Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. <i>Brain Communications</i> , 2020, 2, fcz050.	1.5	46
33	Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1188-1197.	1.9	13
34	Guidelines for the management of glucocorticoids during the perioperative period for patients with adrenal insufficiency. <i>Anaesthesia</i> , 2020, 75, 654-663.	1.8	93
35	Fighting liver fat. <i>Endocrine Connections</i> , 2020, 9, R173-R186.	0.8	4
36	Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo. <i>Journal of Endocrinology</i> , 2020, 245, 207-218.	1.2	9

#	ARTICLE	IF	CITATIONS
37	Guidance for the prevention and emergency management of adult patients with adrenal insufficiency. <i>Clinical Medicine</i> , 2020, 20, 371-378.	0.8	44
38	Glucocorticoid Metabolism and Activation. , 2019, , 90-103.		3
39	AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 67-80.	1.5	52
40	Recovery of the Hypothalamo-Pituitary-Adrenal Axis After Transsphenoidal Adenectomy for Non- α -ACTH-Secreting Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5316-5324.	1.8	19
41	Increased central adiposity and decreased subcutaneous adipose tissue 11 β -hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance: A longitudinal cohort study. <i>Clinical Endocrinology</i> , 2019, 91, 72-81.	1.2	9
42	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. <i>Frontline Gastroenterology</i> , 2019, 10, 337-346.	0.9	48
43	Author's Reply: Does increased 11 β HSD α 1 activity induce adverse metabolic phenotype only in lean?. <i>Clinical Endocrinology</i> , 2019, 90, 849-850.	1.2	0
44	Human and murine steroid 5 β -reductases (AKR1D1 and AKR1D4): insights into the role of the catalytic glutamic acid. <i>Chemico-Biological Interactions</i> , 2019, 305, 163-170.	1.7	8
45	AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 218-227.	1.2	16
46	Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. <i>Clinical Endocrinology</i> , 2019, 90, 440-448.	1.2	16
47	Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 749-760.	2.2	23
48	Very low calorie diets are associated with transient ventricular impairment before reversal of diastolic dysfunction in obesity. <i>International Journal of Obesity</i> , 2019, 43, 2536-2544.	1.6	12
49	PYY plays a key role in the resolution of diabetes following bariatric surgery in humans. <i>EBioMedicine</i> , 2019, 40, 67-76.	2.7	65
50	A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. <i>JCI Insight</i> , 2019, 4, .	2.3	55
51	A potential role for hepcidin in obesity-driven colorectal tumourigenesis. <i>Oncology Reports</i> , 2018, 39, 392-400.	1.2	6
52	Evaluating the Fat Distribution in Idiopathic Intracranial Hypertension Using Dual-Energy X-ray Absorptiometry Scanning. <i>Neuro-Ophthalmology</i> , 2018, 42, 99-104.	0.4	42
53	The 5-HT _{2C} receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers. <i>Psychopharmacology</i> , 2018, 235, 257-267.	1.5	14
54	Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. <i>Diabetic Medicine</i> , 2018, 35, 89-98.	1.2	35

#	ARTICLE	IF	CITATIONS
55	Treatment with PBI-4050 in patients with Alstr�m syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial. <i>BMC Endocrine Disorders</i> , 2018, 18, 88.	0.9	15
56	PWE-075�...Managing nafld via a multidisciplinary clinic approach improves liver health and is cost effective. , 2018, , .		0
57	Sex Differences in Hepatic De Novo Lipogenesis with Acute Fructose Feeding. <i>Nutrients</i> , 2018, 10, 1263.	1.7	35
58	Learning pharmacokinetic models for in vivo glucocorticoid activation. <i>Journal of Theoretical Biology</i> , 2018, 455, 222-231.	0.8	6
59	The Short Synacthen (Corticotropin) Test Can Be Used to Predict Recovery of Hypothalamo-Pituitary-Adrenal Axis Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3050-3059.	1.8	48
60	Liver biochemical abnormalities in Turner syndrome: A comprehensive characterization of an adult population. <i>Clinical Endocrinology</i> , 2018, 89, 667-676.	1.2	21
61	The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1834-1841.	1.8	58
62	Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2855.	1.8	38
63	Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017, 30, 284-293.	0.7	27
64	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. <i>Frontline Gastroenterology</i> , 2017, 8, 252-259.	0.9	22
65	Cortisol Metabolism as a Regulator of the Tissue-Specific Glucocorticoid Action. , 2017, , 271-301.		0
66	AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3327-3339.	1.8	133
67	Baseline morning cortisol level as a predictor of pituitary�adrenal reserve: a comparison across three assays. <i>Clinical Endocrinology</i> , 2017, 86, 177-184.	1.2	53
68	11�HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice. <i>Endocrinology</i> , 2017, 158, 1964-1976.	1.4	26
69	Acute Hypercortisolemia Exerts Depot-Specific Effects on Abdominal and Femoral Adipose Tissue Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1091-1101.	1.8	8
70	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. <i>JCI Insight</i> , 2017, 2, .	2.3	187
71	Advanced non�alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstr�m syndrome. <i>Liver International</i> , 2016, 36, 1704-1712.	1.9	23
72	Male 11�HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. <i>Endocrinology</i> , 2016, 157, 3493-3504.	1.4	16

#	ARTICLE	IF	CITATIONS
73	THE ANDRO-METABOLIC SIGNATURE OF IIH COMPARED WITH PCOS AND SIMPLE OBESITY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, e1.46-e1.	0.9	2
74	Cortisol metabolism, postnatal depression and weight changes in the first 12 months postpartum. <i>Clinical Endocrinology</i> , 2016, 85, 881-890.	1.2	24
75	Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO). <i>Physiological Reports</i> , 2016, 4, e12944.	0.7	21
76	Dual-5 α -Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 103-113.	1.8	50
77	Non-alcoholic fatty liver disease and diabetes. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1096-1108.	1.5	396
78	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet, The</i> , 2016, 387, 679-690.	6.3	1,397
79	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, 399-408.	1.8	308
80	SFRP2 Is Associated with Increased Adiposity and VEGF Expression. <i>PLoS ONE</i> , 2016, 11, e0163777.	1.1	27
81	Response to the Letter: "Dual-5 α -Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, L48-L49.	1.8	0
82	Gender-Specific Differences in Skeletal Muscle 11 β -HSD1 Expression Across Healthy Aging. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2673-2681.	1.8	67
83	Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 121.	1.6	12
84	Glucocorticoids and non-alcoholic fatty liver disease. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 154, 94-103.	1.2	137
85	Association between hypercortisolaemia and adipose tissue blood flow in vivo. <i>Lancet, The</i> , 2015, 385, S63.	6.3	5
86	Tissue Specific Regulation of Glucocorticoids in Severe Obesity and the Response to Significant Weight Loss Following Bariatric Surgery (BARICORT). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1434-1444.	1.8	35
87	Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. <i>Lancet, The</i> , 2015, 385, S16.	6.3	43
88	5 α -Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes. <i>Endocrinology</i> , 2015, 156, 2863-2871.	1.4	38
89	The Dehydrogenase Hypothesis. <i>Advances in Experimental Medicine and Biology</i> , 2015, 872, 353-380.	0.8	19
90	Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. <i>European Journal of Endocrinology</i> , 2015, 173, 633-642.	1.9	116

#	ARTICLE	IF	CITATIONS
91	Diagnosis and management of adrenal insufficiency. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 216-226.	5.5	297
92	Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. <i>Journal of Clinical Investigation</i> , 2015, 125, 501-520.	3.9	163
93	Differential Adipose Tissue Gene Expression Profiles in Abacavir Treated Patients That May Contribute to the Understanding of Cardiovascular Risk: A Microarray Study. <i>PLoS ONE</i> , 2015, 10, e0117164.	1.1	5
94	Central Hypoadrenalism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4027-4036.	1.8	80
95	11 β -HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2482-91.	3.3	225
96	Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 33-41.	0.2	41
97	Development of Hepatocellular Carcinoma in a Murine Model of Nonalcoholic Steatohepatitis Induced by Use of a High-Fat/Fructose Diet and Sedentary Lifestyle. <i>American Journal of Pathology</i> , 2014, 184, 1550-1561.	1.9	91
98	Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1027-1036.	1.8	231
99	IGFALS Gene Dosage Effects on Serum IGF-I and Glucose Metabolism, Body Composition, Bone Growth in Length and Width, and the Pharmacokinetics of Recombinant Human IGF-I Administration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E703-E712.	1.8	25
100	Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 651-660.	2.2	50
101	Longitudinal changes in glucocorticoid metabolism are associated with later development of adverse metabolic phenotype. <i>European Journal of Endocrinology</i> , 2014, 171, 433-442.	1.9	24
102	Understanding androgen action in adipose tissue. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 277-284.	1.2	120
103	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5 α -Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 161-171.	1.8	131
104	11 β -Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. <i>Endocrine Reviews</i> , 2013, 34, 525-555.	8.9	152
105	Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 234-242.	1.9	204
106	A comparative quality assessment of evidence-based clinical guidelines in endocrinology. <i>Clinical Endocrinology</i> , 2013, 78, 183-190.	1.2	35
107	Regulation of Lipid Metabolism by Glucocorticoids and 11 β -HSD1 in Skeletal Muscle. <i>Endocrinology</i> , 2013, 154, 2374-2384.	1.4	30
108	Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. <i>BMJ Open</i> , 2013, 3, e003995.	0.8	41

#	ARTICLE	IF	CITATIONS
109	Glucocorticoids Fail to Cause Insulin Resistance in Human Subcutaneous Adipose Tissue In Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1631-1640.	1.8	53
110	Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E1134-E1144.	1.8	50
111	Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders. <i>European Journal of Endocrinology</i> , 2013, 169, R27-R37.	1.9	80
112	Loss of 5 α -Reductase Type 1 Accelerates the Development of Hepatic Steatosis but Protects Against Hepatocellular Carcinoma in Male Mice. <i>Endocrinology</i> , 2013, 154, 4536-4547.	1.4	67
113	Hormonal Regulation of Lipogenesis. <i>Vitamins and Hormones</i> , 2013, 91, 1-27.	0.7	15
114	Evidence for a Shift to Anaerobic Metabolism in Adipose Tissue in Efavirenz-Containing Regimens for HIV with Different Nucleoside Backbones. <i>Antiviral Therapy</i> , 2012, 17, 495-507.	0.6	9
115	Lack of Significant Metabolic Abnormalities in Mice with Liver-Specific Disruption of 11 β -Hydroxysteroid Dehydrogenase Type 1. <i>Endocrinology</i> , 2012, 153, 3236-3248.	1.4	61
116	Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2012, 61, 484-500.	6.1	71
117	The diagnosis of non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 205-206.	1.9	0
118	A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2012, 7, e29531.	1.1	83
119	Regulation of Lipogenesis by Glucocorticoids and Insulin in Human Adipose Tissue. <i>PLoS ONE</i> , 2011, 6, e26223.	1.1	112
120	P86 5 α -reductase-1 knockout promotes steatosis but protects against hepatocarcinogenesis in a murine model of NAFLD. <i>Gut</i> , 2011, 60, A39-A40.	6.1	0
121	Current therapeutic strategies in non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 692-702.	2.2	92
122	Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 525-540.	1.9	254
123	Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue. <i>Nutrition and Diabetes</i> , 2011, 1, e3-e3.	1.5	12
124	Cerebrospinal Fluid Corticosteroid Levels and Cortisol Metabolism in Patients with Idiopathic Intracranial Hypertension: A Link between 11 β -HSD1 and Intracranial Pressure Regulation?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5348-5356.	1.8	84
125	Mortality in Patients with Pituitary Disease. <i>Endocrine Reviews</i> , 2010, 31, 301-342.	8.9	331
126	Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2010, 341, c2701-c2701.	2.4	257

#	ARTICLE	IF	CITATIONS
127	The Role of 11 β -Hydroxysteroid Dehydrogenase 1 in Adipogenesis in Thyroid-Associated Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 398-406.	1.8	25
128	Pathogenesis of non-alcoholic fatty liver disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 71-83.	0.2	581
129	11 β -Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1067-1076.	1.9	44
130	11 β -Hydroxysteroid Dehydrogenase Type 1 Regulates Glucocorticoid-Induced Insulin Resistance in Skeletal Muscle. <i>Diabetes</i> , 2009, 58, 2506-2515.	0.3	146
131	Increased 5 α -Reductase Activity and Adrenocortical Drive in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3558-3566.	1.8	97
132	Selective Inhibitors of 11 β -Hydroxysteroid Dehydrogenase Type 1 for Patients With Metabolic Syndrome: Is the Target Liver, Fat, or Both?. <i>Diabetes</i> , 2009, 58, 14-15.	0.3	31
133	Nonclassic Lipoid Congenital Adrenal Hyperplasia Masquerading as Familial Glucocorticoid Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3865-3871.	1.8	138
134	Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance?. <i>Clinical Endocrinology</i> , 2009, 70, 863-869.	1.2	69
135	Effects of glucocorticoids on fat mass and the therapeutic potential of targeting 11 β -hydroxysteroid dehydrogenase type 1 in obesity. <i>Clinical Lipidology</i> , 2009, 4, 439-447.	0.4	0
136	Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. <i>Antiviral Therapy</i> , 2009, 14, 1089-1100.	0.6	25
137	11 β -Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. <i>Diabetologia</i> , 2008, 51, 2003-2011.	2.9	51
138	Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. <i>European Respiratory Journal</i> , 2008, 32, 1047-1052.	3.1	34
139	Reduced Glucocorticoid Production Rate, Decreased 5 α -Reductase Activity, and Adipose Tissue Insulin Sensitization After Weight Loss. <i>Diabetes</i> , 2008, 57, 1536-1543.	0.3	79
140	Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11 β -Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5 α -Reductase Activity. <i>Diabetes</i> , 2008, 57, 2652-2660.	0.3	117
141	Lack of Hexose-6-Phosphate Dehydrogenase Impairs Lipid Mobilization from Mouse Adipose Tissue. <i>Endocrinology</i> , 2008, 149, 2584-2591.	1.4	35
142	Steroid Biomarkers and Genetic Studies Reveal Inactivating Mutations in Hexose-6-Phosphate Dehydrogenase in Patients with Cortisone Reductase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3827-3832.	1.8	79
143	A novel selective 11 β -hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. <i>Journal of Endocrinology</i> , 2008, 197, 297-307.	1.2	80
144	Inhibition of 11 β -Hydroxysteroid Dehydrogenase Type 1 Activity in Vivo Limits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 857-864.	1.8	92

#	ARTICLE	IF	CITATIONS
145	Reduced 11 β -hydroxysteroid dehydrogenase type 1 activity in obese boys. <i>European Journal of Endocrinology</i> , 2007, 157, 319-324.	1.9	21
146	11 β -Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. <i>Journal of Biological Chemistry</i> , 2007, 282, 27030-27036.	1.6	48
147	Characterisation of 11 β -hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat. <i>Journal of Endocrinology</i> , 2007, 192, 279-288.	1.2	32
148	Glucocorticoid Modulation of Insulin Signaling in Human Subcutaneous Adipose Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4332-4339.	1.8	60
149	Modulation of glucocorticoid action and the treatment of type-2 diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 607-619.	2.2	53
150	Corticosteroids, 11 β -Hydroxysteroid Dehydrogenase Isozymes and the Rabbit Choroid Plexus. <i>Journal of Neuroendocrinology</i> , 2007, 19, 614-620.	1.2	42
151	Depot-specific prostaglandin synthesis in human adipose tissue: A novel possible mechanism of adipogenesis. <i>Gene</i> , 2006, 380, 137-143.	1.0	46
152	The Long-Term Predictive Accuracy of the Short Synacthen (Corticotropin) Stimulation Test for Assessment of the Hypothalamic-Pituitary-Adrenal Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 43-47.	1.8	125
153	Expression profiling of 11 β -hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 327-340.	1.1	53
154	Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 β -hydroxysteroid dehydrogenase type 1. <i>Journal of Molecular Endocrinology</i> , 2005, 34, 675-684.	1.1	153
155	11 β -Hydroxysteroid dehydrogenase type 1 as a therapeutic target in the metabolic syndrome. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005, 2, 93-96.	0.5	5
156	Mechanisms of Disease: selective inhibition of 11 β -hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2005, 1, 92-99.	2.9	68
157	11 β -hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target. <i>Minerva Endocrinologica</i> , 2005, 30, 37-46.	1.7	5
158	11 β -Hydroxysteroid Dehydrogenase Type 1 Activity in Lean and Obese Males with Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4755-4761.	1.8	153
159	Weight Loss Increases 11 β -Hydroxysteroid Dehydrogenase Type 1 Expression in Human Adipose Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2711-2716.	1.8	85
160	Androgen generation in adipose tissue in women with simple obesity – a site-specific role for 17 β -hydroxysteroid dehydrogenase type 5. <i>Journal of Endocrinology</i> , 2004, 183, 331-342.	1.2	154
161	“Cushing’s disease of the omentum” Fat or fiction?. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 171-174.	1.8	24
162	11 β -Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response. <i>Endocrine Reviews</i> , 2004, 25, 831-866.	8.9	897

#	ARTICLE	IF	CITATIONS
163	Mutations in the genes encoding 11 β -hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. <i>Nature Genetics</i> , 2003, 34, 434-439.	9.4	276
164	Treating Hypertension in Diabetic Nephropathy. <i>Diabetes Care</i> , 2003, 26, 1802-1805.	4.3	24
165	Low-Dose Growth Hormone Inhibits 11 β -Hydroxysteroid Dehydrogenase Type 1 but Has No Effect upon Fat Mass in Patients with Simple Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2113-2118.	1.8	39
166	Expression of 11 β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue Is Not Increased in Human Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5630-5635.	1.8	196
167	Absence of Cushingoid Phenotype in a Patient with Cushing's Disease due to Defective Cortisone to Cortisol Conversion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 57-62.	1.8	61
168	The Functional Consequences of 11 β -Hydroxysteroid Dehydrogenase Expression in Adipose Tissue. <i>Hormone and Metabolic Research</i> , 2002, 34, 746-751.	0.7	38
169	Cortisol, 11 β -hydroxysteroid dehydrogenase type 1 and central obesity. <i>Trends in Endocrinology and Metabolism</i> , 2002, 13, 94-96.	3.1	43
170	11 β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 IN DIFFERENTIATING OMENTAL HUMAN PREADIPOCYTES: FROM DE-ACTIVATION TO GENERATION OF CORTISOL. <i>Endocrine Research</i> , 2002, 28, 449-461.	0.6	64
171	Absence of Cushingoid Phenotype in a Patient with Cushing's Disease due to Defective Cortisone to Cortisol Conversion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 57-62.	1.8	48
172	Cortisol metabolism and the role of 11 β -hydroxysteroid dehydrogenase. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2001, 15, 61-78.	2.2	129
173	Association between premature mortality and hypopituitarism. <i>Lancet</i> , The, 2001, 357, 425-431.	6.3	930
174	Growth Hormone, Insulin-Like Growth Factor-I and the Cortisol-Cortisone Shuttle. <i>Hormone Research in Paediatrics</i> , 2001, 56, 1-6.	0.8	61
175	Regulation of Expression of 11 β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines*. <i>Endocrinology</i> , 2001, 142, 1982-1989.	1.4	215
176	The Role of 11 β -Hydroxysteroid Dehydrogenase in Central Obesity and Osteoporosis. <i>Endocrine Research</i> , 2000, 26, 711-722.	0.6	37
177	Regulation of Expression of 11 β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines. , 0, .		63
178	Gender specific metabolic phenotype in the 5[beta]-reductase knockout mouse. <i>Endocrine Abstracts</i> , 0, , .	0.0	1